We identify and share funding opportunities as they arise to help advance MPT research and development. The items below are listed from the earliest to latest application due dates. We encourage you to browse below and contact us if you hear of any new opportunities.
NIH Small Business (SBIR/STTR) Funding
Waiver Topic (NIAID):
Chemical prophylaxis: Long-acting (minimum 30 days) sustained- or extended-release pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and multipurpose prevention technologies (MPTs) for systemic protection from infection.
NIH Biological Testing Facility for Contraception & Reproductive Health (PAR-27-111)
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has released a new Notice of Funding Opportunity (PAR-27-111) providing investigators with access to the NIH Biological Testing Facility (BTF) to support contraceptive and reproductive health product development.
Applicants do not need to have current NIH funding to apply, and non-U.S. organizations are eligible to submit applications.
Male Contraceptive Initiative (MCI)
The MCI supports the career development of students and research trainees directly through our Success program. MCI accepts applications on a rolling basis for any activity or need that advances the career of a trainee interested in the field of male contraception. Eligible activities include travel grants, digital conferences, workshops, and other professional development opportunities.
MCI Trainee Success Application
Apply here
Strengthening Grant
Strengthening Grants provide funding for advocacy initiatives led by small to medium-sized civil society organisations working to advance sexual and reproductive health and rights (SRHR). Up to 40% of the grant may be allocated to organisational development activities that enhance capacity, strengthen systems, and improve overall effectiveness.
Learn more about this opportunity here.
Development of Collaborative Research Facilities or Research-Resource Facilities
The NIH Office of Research Infrastructure Programs (ORIP) has issued a Notice of Funding Opportunity (NOFO) for the development of research or resource facilities that advance human-based tools for HIV/AIDS and other biomedical research.
This NOFO is soliciting applications from institutions that want to establish or expand multidisciplinary collaborative research spaces, core labs, or state-of-the-art facilities like imaging centers, biorepositories, and other shared-use facilities that support emerging non-animal methods or human-based research technologies.
Learn more about this opportunity here.
Catalytic Opportunity Fund: For Introduction and Scale Up of New and Lesser Used Reproductive Health Products
The Clinton Health Access Initiative (CHAI) has opened its Catalytic Opportunity Fund (COF) providing short-term grants to fund catalytic activities that support introduction or scale-up of reproductive health products including for the hormonal IUD. The COF is a flexible pool of funds that is administered by CHAI and managed by global steering committees.
Learn more about this opportunity here.
Building Disciplinary Research Careers in Women’s Health
The NIH Office of Research on Women’s Health (ORWH), along with participating NIH Institutes and Offices, offers the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Career Development Programs. To support junior faculty members (BIRCWH Scholars) in their mentored research careers. This program fosters interdisciplinary research in areas like basic, translational, data science, and health services, all focused on women’s health.
Learn more about this opportunity here.
FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests
The FDA has launched a new “Commissioner’s National Priority Voucher” (CNPV) program to speed up drug review times—from up to a year to just one or two months. These non-transferable vouchers are reserved for companies addressing key U.S. priorities like health crises, innovation, unmet public health needs, and domestic manufacturing. Eligibility will be determined by FDA Commissioner Marty Makary, and each voucher remains valid through company ownership changes. The process includes early submission of key documents and a one-day, team-based review approach. The program also aligns with broader FDA efforts to streamline approvals using AI and pre-trial submissions. Vouchers expire after two years.
Learn more about this opportunity here.